A Phase I clinical trial of AT101, a new CAR T cell therapy targeting CD19 through a distinct binding mechanism, has shown a 100% complete response rate in patients with relapsed or refractory B cell non-Hodgkin's lymphoma. The treatment was found to be safe with manageable side effects and is expected to build upon the effectiveness o...
A Rutgers study found that mindfulness-Oriented Recovery Enhancement (MORE) can improve women's emotion regulation and impulse control, reducing opioid cravings. The program boosted communication between brain areas involved in controlling negative emotions and drug cravings.
A Phase IIa international study found that a combination of zanidatamab, palbociclib, and fulvestrant improved progression-free survival by 12 months with durable responses. The treatment regimen is being developed for heavily pretreated patients with HER2+/HR+ metastatic breast cancer.
A new study in mice shows that a hybrid treatment combining a drug and a protein fragment can prevent the growth of blood cancer cells by targeting the RAS gene mutation. The treatment, which blocks cell division and multiplication, has shown promising results in live animals with multiple myeloma tumors.
Researchers used NIRS to track oxygenated hemoglobin levels in infant brains responding to gentle touch. They found similar response times across age groups, but varying signal amplitudes that may be linked to changes in blood flow and erythropoietin production.
Researchers uncover the role of IGF2BP2 in responding to cardiac stress, highlighting its potential reversibility and clinical relevance. Elevated IGF2BP2 expression leads to dilated cardiomyopathy, but controlled reduction prompts recovery.
The study found that dasatinib and blinatumomab combination treatment resulted in excellent median overall survival and disease-free survival times for patients 65 and older with Philadelphia chromosome-positive acute lymphoblastic leukemia. The regimen confirmed benefits of this treatment are durable, with a median overall survival of...